NCT01715636View on ClinicalTrials.gov

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men
Interventions
DRUG

Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg

Trial Locations (4)

2000

Sydney Sexual Heatlh Centre, Sydney

2010

St Vincents Hospital, Sydney

3004

The Alfred Hospital, Melbourne

3053

Melbourne Sexual Health Centre, Melbourne

All Listed Sponsors
lead

Andrew Carr

OTHER

NCT01715636 - Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. | Biotech Hunter | Biotech Hunter